Wedbush Expects Weaker Earnings for Telix Pharmaceuticals

Key Points

• Wedbush has lowered its Q3 2025 EPS estimate for Telix Pharmaceuticals from $0.14 to $0.03, maintaining an "Outperform" rating with a target price of $22.00.
• The consensus EPS estimate for the full year 2025 has dropped to $0.24, with additional Q4 2025 and FY2026 estimates also provided.
• Telix Pharmaceuticals currently has a consensus rating of "Buy" from four analysts, reflecting positive sentiment with an average target price of $22.33.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Stock analysts at Wedbush dropped their Q3 2025 earnings per share estimates for Telix Pharmaceuticals in a research report issued on Thursday, August 21st. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of $0.03 for the quarter, down from their previous forecast of $0.14. Wedbush has a "Outperform" rating and a $22.00 price target on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. Wedbush also issued estimates for Telix Pharmaceuticals' Q4 2025 earnings at $0.04 EPS, FY2025 earnings at $0.07 EPS, Q1 2026 earnings at $0.06 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.10 EPS, Q4 2026 earnings at $0.12 EPS, FY2026 earnings at $0.37 EPS, Q1 2027 earnings at $0.14 EPS, Q2 2027 earnings at $0.15 EPS and FY2027 earnings at $0.65 EPS.

Several other research firms have also issued reports on TLX. William Blair reiterated an "outperform" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, July 9th. HC Wainwright assumed coverage on Telix Pharmaceuticals in a research report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price objective for the company. Four investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Telix Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $22.33.

Telix Pharmaceuticals Price Performance

TLX stock traded down $0.44 during midday trading on Monday, hitting $12.10. The stock had a trading volume of 233,577 shares, compared to its average volume of 46,624. Telix Pharmaceuticals has a 52 week low of $10.50 and a 52 week high of $30.36. The stock has a 50-day simple moving average of $14.30 and a 200 day simple moving average of $16.19. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TLX. Pier Capital LLC bought a new position in Telix Pharmaceuticals during the second quarter worth about $3,037,000. Russell Investments Group Ltd. bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $975,000. Jane Street Group LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $564,000. ABC Arbitrage SA bought a new position in shares of Telix Pharmaceuticals during the 1st quarter valued at about $451,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in shares of Telix Pharmaceuticals during the 2nd quarter valued at about $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.